Advances in Chronic Kidney Disease
Volume 12, Issue 4 , Pages 418-423 , October 2005

A Public Health Action Plan Is Needed for Chronic Kidney Disease

  • Anton C. Schoolwerth

      Affiliations

    • Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA
    • Section of Hypertension/Nephrology, Dartmouth Medical School, Hanover, NH
    • Corresponding Author InformationAddress correspondence to Anton C. Schoolwerth, MD, MSHA, One Medical Center Drive, 2M, Lebanon, NH 03756
    • ,
  • Michael M. Engelgau

      Affiliations

    • Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA
    • ,
  • Thomas H. Hostetter

      Affiliations

    • National Kidney Disease Education Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

References 

  1. Vinicor F . Is diabetes a public-health disorder? . Diabetes Care . 1994;17(suppl 1):22–27
  2. Saadine JB . Vision loss (A public health problem?) . Ophthalmology . 2003;110:253–254
  3. Coresh J , Astor BC , Greene T , et al.   Prevalence of chronic kidney disease and decreased kidney function in the adult US population (Third National Health and Nutrition Examination Survey) . Am J Kidney Dis . 2003;41:1–12
  4. US Renal Data System: USRDS 2002, 2003 and 2004 annual data reports. Atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002, 2003, 2004
  5. Pirtle CJ , Schoolwerth AC , Giles WH , Brown DW , Mokdad AH , Ford ES . State-specific trends in chronic kidney disease-United States, 1990-2001 . MMWR Morb Mortal Wkly Rep . 2004;53:918–920
  6. Merrill RM , Kessler LG , Udler JM , et al.   Comparison of risk estimates for selected diseases and causes of death . Prev Med . 1999;28:179–193
  7. Kiberd BA , Clase CM . Cumulative risk for developing end-stage renal disease in the US population . J Am Soc Nephrol . 2002;13:1635–1644
  8. Xue JL , Ma JZ , Louis TA , et al.   Forecast of the number of patients with end-stage renal disease in the United States to the year 2010 . J Am Soc Nephrol . 2001;12:2753–2758
  9. Gilbertson D , Solid C , Xue JL , et al.   Projecting the US ESRD population by 2030 . San Diego, CA: US Renal Data System; 2003; Data presented at the 2003 American Society of Nephrology Annual Meeting, Available at: http://www.usrds.org/presentations_2003.htm. Accessed August 10, 2005
  10. Anavekar NS , McMurray JJV , Velazquez EJ , et al.   Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction . N Engl J Med . 2004;351:1285–1295
  11. Go AS , Chertow GM , Fan D , et al.   Chronic kidney disease and risks of death, cardiovascular events, and hospitalization . N Engl J Med . 2004;351:1296–1305
  12. Menon V , Sarnak MJ . The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease (A high-risk combination) . Am J Kidney Dis . 2005;45:223–232
  13. Sarnak MJ , Levey AS , Schoolwerth AC , et al.   Kidney disease as a risk factor for development of cardiovascular disease (A statement from the councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology and epidemiology and prevention) . Circulation . 2003;108:2154–2169
  14. Mokdad AH , Marks JS , Stroup DF , et al.   Actual causes of death in the United States, 2000 . JAMA . 2004;291:1238–1245
  15. Hunsicker LG . The consequences and costs of chronic kidney disease . J Am Soc Nephrol . 2004;15:1363–1364
  16. Smith DH , Gullion CM , Nichols G , et al.   Cost of medical care from chronic kidney disease and comorbidity among enrollees in a large HMO population . J Am Soc Nephrol . 2004;15:1300–1306
  17. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease (Evaluation, classification and stratification) . Am J Kidney Dis . 2002;39(suppl 1):S1–S266
  18. de Jong PE , Brenner BM . From secondary to primary prevention of progressive renal disease (The case for screening for albuminuria) . Kidney Int . 2004;66:2109–2118
  19. American Diabetes Association . Nephropathy in diabetes . Diabetes Care . 2004;27(suppl 1):S79–S83
  20. Eknoyan G , Hostetter T , Bakris GL , et al.   Proteinuria and other markers of chronic kidney disease (A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)) . Am J Kidney Dis . 2003;42:617–622
  21. Boulware LE , Jaar BG , Tarver-Carr ME , et al.   Screening for proteinuria in US adults (A cost-effectiveness analysis) . JAMA . 2003;290:3101–3114
  22. Parving HH , Andersen AR , Smidt UM , et al.   Early aggressive antihypertensive treatment reduces the rate of decline in kidney function in diabetic nephropathy . Lancet . 1983;1:1175–1179
  23. Lewis EJ , Hunsicker LG , Bain RP , et al.   The effect of angiotensin converting enzyme inhibition on diabetic nephropathy . N Engl J Med . 1993;329:1456–1462
  24. Maschio G , Alberti D , Janin G , et al.   Effect of angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency . N Engl J Med . 1996;334:939–945
  25. The Gruppo Italiano di Studi Epidemiologici in Nephrologia (GISEN) Group . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy . Lancet . 1997;349:1857–1863
  26. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  27. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  28. Pedrini MT , Levey AS , Lau J , et al.   The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases (A meta-analysis) . Ann Intern Med . 1996;124:627–632
  29. Ruggenenti P , Perna A , Remuzzi G . ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: a post hoc analysis of the REIN Trial results . J Am Soc Nephrol . 2001;12:2832–2837
  30. Bianchi S , Bigazzi R , Caiazza A , et al.   A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease . Am J Kidney Dis . 2003;41:565–570
  31. Morales E , Valero A , Léon M , et al.   Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies . Am J Kidney Dis . 2001;41:319–327
  32. Schiffl H , Lang SM , Fischer R . Stopping smoking slows accelerated progression of renal failure in primary renal disease . J Nephrol . 2002;15:270–274
  33. Xue JL , St. Peter WL , Ebben JP , et al.   Anemia treatment in the pre-ESRD period and associated mortality in elderly patients . Am J Kidney Dis . 2002;40:1153–1161
  34. Gouva C , Nikolopoulos P , Ioannidis JP , et al.   Treating anemia early in renal failure patients slows the decline of renal function (A randomized controlled trial) . Kidney Int . 2004;66:753–760
  35. Hillege HL , Fidler V , Diercks GF , et al.   Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population . Circulation . 2002;106:1777–1782
  36. Jensen JS , Borch-Johnsen K , Jensen G , et al.   Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically health subjects . Clin Sci (Colch) . 1995;88:629–633
  37. Asselbergs FW , Diercks GFH , Hillege HL , et al.   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria . Circulation . 2004;110:2809–2816
  38. Mathiesen ER , Hommel E , Hansen HP , et al.   Randomized-control trial of long-term efficacy of captopril on preservation of kidney function in normotensive patients with insulin-dependent diabetes and microalbuminuria . BMJ . 1999;23:1478–1485
  39. Lacourciere Y , Belanger A , Godin C , et al.   Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy . Kidney Int . 2000;58:762–769
  40. Mogensen CE . Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria . Diabetes . 1990;39:761–767
  41. Nelson RG , Bennet PH , Beck GJ , et al.   Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus . N Engl J Med . 1996;335:1636–1642
  42. Pinto-Sietsma SJ , Janssen WMT , Hillege HL , et al.   Urinary albumin excretion is associated with renal functional abnormalities in a non-diabetic population . J Am Soc Nephrol . 2000;11:1882–1888
  43. McClellan WM , Knight DF , Karp H , et al.   Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients (important differences between practice and published guidelines) . Am J Kidney Dis . 1997;29:368–375
  44. Obrador GT , Ruthazer R , Arora P , et al.   Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States . J Am Soc Nephrol . 1999;10:1793–1800
  45. Nissenson AR , Collins AJ , Hurley J , et al.   Opportunities for improving the care of patients with chronic renal insufficiency (Current practice patterns) . J Am Soc Nephrol . 2001;12:1713–1720
  46. Coresh J , Byrd-Holt D , Astor BC , et al.   Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000 . J Am Soc Nephrol . 2005;16:180–188
  47. Levey AS , Coresh J , Balk E , et al.   National Kidney Foundation practice guidelines for chronic kidney disease (Evaluation, classification, and stratification) . Ann Intern Med . 2003;139:137–147
  48. Parker TF , Blantz R , Hostetter T , et al.  Council of American Kidney Societies   The chronic kidney disease initiative . J Am Soc Nephrol . 2004;15:708–716
  49. Hostetter TH , Lising M . National Kidney Disease Education Program . J Am Soc Nephrol . 2003;14(suppl 2):S114–S116

 The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the funding agency.

PII: S1548-5595(05)00125-4

doi: 10.1053/j.ackd.2005.07.012

Advances in Chronic Kidney Disease
Volume 12, Issue 4 , Pages 418-423 , October 2005

Article Tools